Sumitomo Chemical
Search results
Sumitomo Pharma – a company with global business platforms. Sumitomo Pharma has established strong business foundations in Japan, the United States, and Chinese mainland, including local HQ, sales, and R&D functions. North America. A solid business operation system with an excellent management team that can always communicate closely with the ...
- Open602.00High612.00Low580.00
- Mkt Cap230.83BP/E (TTM)N/ADiv & Yield14.00 & 3.47%
- Prev. Close594.0052 Wk. Low279.0052 Wk. High692.00
Related stocks
Sumitomo Pharma Company Limited (住友ファーマ株式会社, Sumitomo Fāma Kabushiki-Gaisha) is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas.
We drive innovative treatments, science, and technology to address patient needs in the critical areas of psychiatry & neurology, oncology, urology, women's health, rare disease, and cell & gene therapy. Learn More.
Specializing in Women's Health, Urology, Psychiatry, Neurology, Oncology & Rare Disease, we offer pharmaceutical products designed to support physical & mental wellbeing. Discover our innovative products today!
SMPA is committed to accelerating scientific and therapeutic breakthroughs on behalf of patients in critical disease areas across psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapies.
About Us. For the betterment of healthcare and fuller lives of people worldwide, we will continue to contribute to the society as a whole, by creating new values based on research and development. Message from the President. More.
Sumitomo Pharma is a research and development-oriented pharmaceutical company that continuously takes on challenges to develop innovative pharmaceuticals and healthcare solutions for the betterment of healthcare and fuller lives of people worldwide.
Mar 15, 2024 · The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in...
Dec 11, 2023 · CAMBRIDGE, Mass., Dec. 11, 2023 / PRNewswire / -- Sumitomo Pharma America, Inc. (SMPA) today announced new data from the ongoing Phase 1/2 first-in-human study of DSP-5336, in patients with relapsed or refractory acute leukemia, presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
